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CHAPTER 1 
 
1.1 The serotonin  
The tryptophan derivative 5-hydroxytryptamine (5-HT) is an important signaling molecule 
in the brain and periphery (Sodhi MS et al. 2004; McLean PG et al. 2007). Serotonin 
present in enteric nerves is synthesized in the enteric nervous system (Yu PL et al. 1999). 
Serotonergic neurons constitute about 2% of all mesenteric neurons. Serotonin is released 
from the bowel when enteric nerves are stimulated (Gershon MD et al 2007). Serotonin is 
synthesized from essential amino acid tryptophan by tryptophan hydroxylase I (TpH-1), a 
rate limiting enzyme present in enterochromaffin cells (EC) (Fig.1), whereas enteric and 
central serotonergic neurons contain TpH-2 (Walther DJ et al.   2003; Cote F et al. 2003). 
EC cells produce and secrete far more serotonin than either central or peripheral 
serotonergic neurons to reach the GI lumen and blood (Tamir H et al. 1985). Overflowing 
serotonin from EC cells, which is taken up and concentrated in platelets, is virtually the 
sole source of blood serotonin; platelets lack TpH. Serotonin exerts its action by binding to 
its receptors (5-HT1 to 5- HT7) present in both intrinsic and extrinsic primary afferent 
neurons. 
Serotonin in tissues metabolized mainly by enzyme monoamine oxidase. In the kidney and 
liver, monoamine oxidase and aldehyde dehydrogenase convert 5-HT to 5-hydroxyindole 
acetic acid (5-HIAA), which is excreted in the urine. Approximately 2–10 mg of 5-HIAA is 
excreted daily by the normal adult as a result of metabolism of endogenous 5-HT. 
Serotonin present in the food, metabolized before entering the blood stream.  
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Fig.1 Serotonin synthesis 
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1.4 The serotonin transporter 
 
Like many other neurotransmitters, 5-HT is predominantly inactivated by transporter-
mediated clearance. Serotonin transporter (SERT) is encoded by a single gene in man as 
well as in commonly used rodent models (Ramamoorthy S et al. 1993). SERTs bear closest 
identity with norepinephrine transporters (NET, SLC6A2) with which they also share 
sensitivity to tricyclic antidepressants (Barker EL et al. 1995). 
Topologically, SERT is a polytopic, integral membrane protein comprised of twelve 
transmembrane domains with cytoplasmic NH2 and COOH termini (Ramamoorthy S et al. 
1993; Blakely RD et al. 1991; Hoffman BJ et al. 1991). The crystal structure of a bacterial 
SLC6A4 transporter, LeuTAa (Yamashita A  et al. 2005; Chen JG  er al. 1998; Torres GE 
et al. 2007), is consistent with the predicted topology of SERT (Henry LK et al. 2006; 
Henry LK et al. 2007) and has permitted the use of homology-based modeling approaches 
to provide a more realistic inspection of key helices that participate in 5-HT recognition as 
well as how 5-HT transport across membranes is achieved. SERT mediates secondary 
active, ion-coupled 5-HT transport, deriving energy for inward 5-HT transport largely from 
the Na
+
 gradient. 
SERT exhibits a coupling stechiometry of one 5-HT: one Na+ and one Cl-, with one K+ 
molecule believed to be effluxed on a separate step of the transport cycle (Rudnick G et al. 
1993). 
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1.5 Structure, expression and function of the SERT protein 
 
SERT belongs to the superfamily of large-solute-carrier transporters and is designated as 
SLC6A4. Human SERT is a monomeric protein encompassing 630 amino acids and 
consists of 12 putative transmembrane domains (TMs), a large extracellular loop between 
TM3 and TM4 that has potential sites for N-glycosylation and large extracellular NH2- and 
C-terminal domains containing potential phosphorylation sites (Murphy D.L et al. 2004, 
Murphy D.L et al. 2008; Spiller R. 2007; Lesch K.P  et al. 2005; Usala T. et al . 2008; 
Rudnick, G. 2006). Amino acids in TM1 and TM3 are major determinants for serotonin 
binding (Kilic F. et al. 2003) and phosphorylation and dephosphorylation processes 
regulate the membrane SERT density (Quick, M.W. 2002).  
SERT expression has been demonstrated in the central nervous system (CNS) of various 
mammalian species (Gill R.K. et al. 2008). The distribution of serotonin transporter in 
human brain was evaluated by mean of binding assays using specific and selective 
radioligands. In particular, the highest concentrations of [3H]paroxetine-specific binding 
sites were found in the substantia nigra, hypothalamus, and hippocampus of human brain. 
Lower values were obtained in the basal ganglia and the thalamus. The specific binding 
was very low in cerebral and cerebellar cortices (Laruelle M. et al.198)  
The neuroanatomical distribution of binding sites for [3H]imipramine and [3H]citalopram 
was assessed by in vitro autoradiography in select regions of the rat and human forebrain. 
To determine involvement of serotonin-containing terminals in the binding of 
[3H]imipramine and [3H]citalopram, binding of these compounds was measured in rats 
after destroying serotonin-containing neurons with 5,7-dihydroxytryptamine (5,7-DHT). 
Treatment with this neurotoxin decreased serotonin content by 90% and reduced 
[3H]citalopram binding to a similar extent. These results demonstrated that [3H]citalopram 
binding was a reliable marker for serotonin-containing terminals. Binding of 
[3H]imipramine was reduced by only 15-35% after 5,7-DHT treatment. These latter results 
suggested that only a small fraction of [3H]imipramine binding to brain sections was 
associated with serotonergic terminals under standard conditions used in autoradiographic 
studies with the ligand. Dose-response effects of fluoxetine and desipramine on 
displacement of [3H]imipramine binding in forebrain regions indicate that the ligand labels 
predominantly high capacity, low affinity binding sites. To determine the utility of the rat 
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brain as a model for [3H]imipramine and [3H]citalopram binding in the human brain, 
binding of the ligands was compared in human and rat hypothalamus, amygdala, and 
hippocampus. The pharmacological characteristics of [3H]imipramine and [3H]citalopram 
binding were similar in the rat and human brain. However, substantial species differences 
were observed in topographic patterns of [3H]imipramine binding within the hippocampus 
and hypothalamus. The distribution of [3H]citalopram binding sites within the amygdala 
and hypothalamus were also strikingly different in rats compared to humans. This work 
provides the first demonstration that marked species differences exist in the topography of 
serotonergic innervation and in the distribution of [3H]imipramine binding sites within the 
rat and human brain regions examined (Duncan GE. Et al. 1992). 
At intestinal level, evidence of SERT expression was initially obtained in rats and guinea 
pigs (Chen J.X. et al. 1998). Recently, SERT mRNA has been detected in normal human 
stomach and intestine, with high density in small intestine (Meier Y. et al. 2007; Van 
Lelyveld N. et al. 2007).  
SERT immunostaining has been observed mainly in human duodenal and ileal epithelial 
cells (Gill R.K. et al. 2008), and it has also been demonstrated in rectal biopsies from 
healthy humans (Coates M.D. et al 2004). However, information on SERT expression in 
the neuromuscular compartments of gastrointestinal tract in humans and animals is lacking. 
SERT operates the reuptake of serotonin through a mechanism associated with co-transport 
of Na
+
 and Cl
-
 and counter-transport of K
+
. As a first step, serotonin, Na
+ 
and Cl
-
 bind a 
single site, accessible from the extracellular space. Then, a conformational change occurs 
that blocks the accessibility of the binding site from the extracellular side and opens access 
to it from the cytoplasm side. In this conformation, serotonin, Na
+
 and Cl
-
 dissociate from 
SERT, and K+ binds to the same site to facilitate a conformational change back to the 
status that allows accessibility from extracellular space (Murphy D.L. et al. 2004).  
In the digestive tract, serotonin is stored in enterochromaffin cells (ECs), which release the 
mediator in response to mechanical or chemical stimuli, and to a lesser extent in some 
intramural enteric neurons. After it is released by ECs, serotonin promotes peristalsis, 
secretion, vasodilation and sensory signalling in the gut via interaction with a complex 
array of serotonergic receptor subtypes. The primary targets of serotonin released from ECs 
are the mucosal projections of afferent neurons. These include extrinsic nerves, which 
transmit gut sensations to the CNS, and intrinsic primary afferent neurons, which initiate 
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peristaltic and secretory reflexes. Serotonin released from myenteric neurons is involved in 
the regulation of digestive motility (Gershon MD. Et al. 2007). 
Thus, changes in SERT activity, resulting from genetic or environmental factors as well as 
pharmacological modulations, are expected to alter functions regulated by serotonergic 
pathways.  
 
 
 
Fig.2: Serotonergic synapse 
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1.4 Molecular structure and transcription of the SERT gene 
 
A single SERT gene has been identified in the human genome. It is located on chromosome 
17q11.2, covers 37.8 kb, comprises 14 exons, encompasses a 630 amino acid open reading 
frame and has three putative polyadenylation sites. The start codon is located in exon-2, the 
protein is coded by the nucleotide sequence running from exon-2 to exon-14 and exon-1 
consists of a noncoding sequence (Ramamoorthy, S. et al 1993; Battersby, S. et al. 1992). 
After initial reports indicating a 14-exon structure, the human SERT gene was shown to 
encode two variants of exon-1 (1A and 1B) (Bradley, C.C. et al 1997). Alternative splicing 
yields two mRNA species comprising exons 1A+2 and 1A+1B+2, and transcription of both 
mRNAs is controlled by a promoter containing highly polymorphic sequences (Figure  3), 
as discussed below. A third mRNA species comprising exons 1B+2 was not identified 
(Bradley, C.C. et al 1997). However, a recent study of normal human intestine has revealed 
three SERT mRNA species, which could arise from alternative splicing (Gill, R.K. et al. 
2008), supporting the hypothesis that the human SERT gene has the potential to generate 
more than two mRNA variants. Evidence for multiple exon-1 sequences was also found in 
rodents (Ozsarac, N. et al. 2002; Sakai, K. et al. 2003). Rat SERT RNA transcript contains 
three noncoding exons (1A, 1B and 1C), and alternative splicing generates mRNAs with 
the exonic combinations 1A+2, 1A+1B+2 or 1C+2. mRNAs comprising 1A+2 or 1A+1B+2 
are thought to be regulated by the same promoter but have different expression patterns 
(1A+2 mRNA occurs mainly in the CNS and adrenal medulla; 1A+2 and 1A+1B+2 
mRNAs occur in the stomach and heart). The 1C+2 mRNA species has been found only in 
the intestine and is likely to be controlled by a distinct promoter (Ozsarac, N. et al. 2002). 
Of note, rat exon-1C shares 68% identity with a region of human SERT gene upstream of 
exon-1B, suggesting the existence ofexon-1C in humans. The identification of a SERT 
mRNA variant containing exon-1C in rodents (Ozsarac, N. et al. 2002) has opened 
interesting perspectives for interpreting the role played by SERT in human gut physiology 
and IBS pathophysiology. 
Indeed, if confirmed in humans, the predominance of 1C+2 mRNA transcripts in the 
intestine would imply that: (i) the polymorphic promoter, which regulates the expression of 
1A+2 mRNA in CNS, might not control SERT expression in the gut; and (ii) as a 
consequence, polymorphisms in the promoter linked to exon-1A might affect SERT 
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expression in the CNS but not in the gut. Thus, studies designed to determine the 
transcriptional regulation of enteric SERT, as well as the exact expression pattern of 
alternatively spliced SERT mRNA transcripts in human intestinal tissues, would contribute 
to clarifying the role of SERT in human gut physiology and IBS pathophysiology. 
 
 
 
 
 
 
 
 Fig.3 Schematic representation of the molecular structure of the serotonin transporter (SERT) gene in 
humans 
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1.5 Polymorphisms of the SERT gene  
 
In the human SERT gene, nonsynonymous mutations, which result in changes of amino 
acid sequence, occur as single nucleotide polymorphisms (SNPs), and their frequency in the 
general population is lower than 1% (Leabman M.K. et al. 2007). 
The possible relationships between nonsynonymous polymorphisms, changes in SERT 
function and implications in pathological conditions, including IBS and other digestive 
disorders, remain undetermined. A variable number of tandem repeats are present in intron-
2 of the SERT gene. The most frequent variants consist of 16- or 17-bp sequences repeated 
nine (STin2*9), ten (STin2*10) or 12 (STin2*12) times, and there is evidence that the 
STin2*12 allele is associated with higher efficiency of SERT transcription than STin2*10 
(Fiskerstrand C.E. et al. 1999). 
The human SERT promoter linked to exon-1A contains a polymorphism, named ‘serotonin 
transporter length polymorphic region’ (5-HTTLPR), which consists of a 43-bp deletion or 
insertion resulting in a short (S) or long (L) allele (Wendland J.R. et al. 2006). In North 
American/European Caucasian populations, the distribution of 5-HTTLPR genotypes is 
32% LL, 49% LS and 19% SS, whereas the SS genotype is represented in 57% of Asians 
(Smits K.M. et al 2004; Serretti A. et al. 2007). The SERT gene also contains an insertion 
or deletion polymorphism (381 bp between 5-HTTLPR and transcription start site) that 
might confer instability to the promoter and might be responsible for variations in SERT 
expression caused by the presence of transcription-factor-binding sites, including activator 
protein 1 (AP1), Elk1 and nuclear factor- kB (Flattem N.L et al. 2000) which can be 
activated in the presence of pathological conditions, such as inflammation. 5-HTTLPR has 
been proposed to influence SERT gene transcription because, in cells transfected with 
SERT promoter, SS homozygosity and LS heterozygosity resulted in a lower 
transcriptional activity (and thereby lower SERT expression and lower uptake efficiency) 
than LL homozygosity (Heils A. et al. 1996). In line with these findings, lymphoblasts from 
subjects with the LL genotype were found to contain higher concentrations of SERT 
mRNA transcripts than cells obtained from SS or SL subjects (Lesch K.P. et al. 1996). 
Subsequently, 5-HTTLPR alleles were shown to differently influence transcription rate, 
expression and function of SERT in brain (Hranilovic D. et al. 2004). Based on these 
observations, clinical investigations have examined possible associations of 5-HTTLPR 
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genotypes with pathophysiology, clinical features or therapeutic response to SSRIs in 
various disorders. 
Advances in SERT genetics suggest that initial assumptions on molecular structure and 
transcriptional activity of 5-HTTLPR are too simplistic and deserve reconsideration. 
According to current evidence, repetitive sequences within 5-HTTLPR can generate four 
subvariants of allele S, six subvariants of allele L and several additional allelic variants 
(Delbruck S.J.W. et al. 1997; Michaelovsky E. et al. 1999; Rasmussen H.B. et al.2007). 
Hu et al. (Hu, X. et al. 2005) have described an A!G SNP within the 43 bp insertion of 5-
HTTLPR that confers the ability to enhance SERT transcription to the A variant of the L 
allele (LA) while rendering the transcriptional activity of the G variant (LG) similar to that 
of the S allele. Kraft et al. (Kraft J.B. et al. 2005) have also identified an A!G SNP 
(designated as rs25531), which has now been recognized as the same 298 SNP discovered 
by Hu et al. (Hu X. et al. 2005). A subsequent analysis of 5-HTTLPR showed that the 
boundaries of the 43 bp insertion or deletion segment can be set in such a way that the A!G 
SNP can lie within both the L and S allele, thereby allowing the S allele to exist as an SA or 
SG variant. Genotyping analysis has indicated a low to moderate frequency for LG and SG 
alleles (6.5% and 0.25%, respectively). However, Kraft et al.  found that rs25531, but not 5-
HTTLPR, was associated with variations in therapeutic effects of SSRIs, and therefore it 
has been argued that 5-HTTLPR and rs25531 should be regarded as two independent 
polymorphisms. To complicate the picture further, reporter gene experiments in transfected 
cells have not confirmed the differential influence of 5-HTTLPR alleles on SERT 
transcription (Sakai K. et al. 2002). Moreover, studies in humans have also failed to 
demonstrate significant correlations between 5-HTTLPR genotypes and SERT expression 
in human brain (Shioe K. et al. 2003; Lim J.E. et al. 2006). These observations raise 
relevant questions about the validity of previous association studies, including those on 
IBS, and suggest the possibility that SERT gene transcription could be influenced by 
polymorphisms in partial linkage disequilibrium with 5-HTTLPR. 
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Fig 4 Schematic representation of the allelic variants resulting from the serotonin transporter length 
polymorphic region (5-HTTLPR) 
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1.6 SERT is regulated  
 
1.6.1 Rapid Reductions in SERT Activity 
 
Initial observations of rapid (2–30 min) downregulation of SERT Vmax following phorbol 
ester treatments provided an initial mechanistic framework that supported loss of SERT 
surface expression in parallel with SERT phosphorylation (Blakely RD. Et al. 1998). 
Because extracellular 5-HT acting through the transporter (as SSRIs block 5-HT effects) 
could prevent phorbol ester-triggered SERT internalization as well as phosphorylation, 
Seversl studies advanced an ‘use it or lose it’ model for SERT regulation. In that study, the 
presence of extracellular 5-HT was proposed to help establish the appropriate level of 
surface expression of SERT proteins needed for amine clearance, presumably through 
reduced endocytosis (Ramamoorthy S. et al. 1999; Blakely RD. et al. 2000). 
 
1.6.1.1 Trafficking-dependent modulation 
The membrane compartments that harbor SERT are distinguished by one or more proteins 
that contribute structural and/or regulatory properties. The first SERT associated protein 
defined was the catalytic subunit of the serine/threonine phosphatase PP2A (PP2Ac). 
Bauman et al. (36) established that okadaic acid-dependent phosphatise activity is enriched 
in SERT immunoprecipitations, consistent with the formation of SERT complexes with 
either protein phosphatase 1 or PP2A. Subsequent immunoblotting of SERT 
immunoprecipitations from transfected cells and brain membranes revealed the presence of 
PP2Ac. Interestingly, the authors found that PP2Ac associations could be eliminated by 
pretreatment of cells with okadaic acid but were stabilized by extracellular 5-HT 
incubation, thus providing one explanation for reduced b-phorbol 12-myristate 13-acetate 
(PMA)-induced SERT phosphorylation that occurs with coincident 5-HT treatments 
(Bauman AL et al.. et al. 2000). The simplest scenario (Figure 5) consistent with the 
existing data thus involves SERT/PP2Ac associations that are enriched in plasma 
membrane domains containing active SERT, whereas less active SERT pools and 
inactivated (and possibly recycling) SERTs being relatively deficient in SERT/PP2Ac 
complexes. 
The plasma membrane SNARE protein syntaxin (Syn1A) has been a well-documented 
associate of a number of neurotransmitter transporters in the SLC6 family including GAT-
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1, the GLYT2 glycine transporter and NET (Blakely et al. 2000). Haase et al. provided 
evidence that Syn1A also associates with SERT (Haase J. et al. 2001). Sung et al. described 
analogous associations of NET with Syn1A that can be disrupted by PKC activators in 
parallel with loss of surface NET expression (Sung U. et al. 2003). The latter studies also 
demonstrated that Syn1A restricts the catalytic function of NET. Comparable evidence for 
catalytic modulation of SERT by Syn1A has not been advanced. Quick (Quick MW. 2003) 
showed that Syn1A associations with SERT dictate whether the transporter moves 5-HT in 
an electroneutral mode, tightly coupled with co-transported ions. When SERT lacks Syn1A 
associations, 5-HT transport occurs in an electrogenic mode, characterized by 
nonstoichiometric ion flux. Possibly, as Sung et al. have proposed for NET, Syn1A 
associations with SERT dictate whether the transporter contributes to membrane 
excitability and/or whether the transporter enters a higher capacity 5-HT transport mode 
(Figure 5). 
Through yeast two-hybrid screening with the carboxy terminus of DAT, Carneiro et al. 
identified the focal adhesion protein Hic-5 as a transporter-binding partner that also binds 
SERT (Carneiro AM. et al. 2002). Hic-5 is a Lin 11, Isl 1, Mec 3 (LIM) domain scaffolding 
protein that binds the carboxy terminus of SERT, similarly to DAT. Hic-5 is found in 
association with SERT in platelets where the majority of Hic-5/SERT associations are 
localized to the CS fraction. 
Because, like SERT, the bulk of Hic-5 is found in the TS fraction, unassociated with the 
transporter, rather than in the CS domain, Carneiro and Blakely advanced the hypothesis 
that PKC activation recruits Hic-5 to SERT. Hic-5 could support or stabilize catalytic 
inactivation of the transporter as well as translocation of SERT to the CS compartment, 
followed by SERT internalization and dissociation of Hic-5. The degree to which this 
model supports SERT function at synapses is currently being investigated. 
Using the yeast two-hybrid assay, Muller et al. identified secretory carrier membrane 
protein 2 (SCAMP2) as a protein that interacts with the amino terminus of SERT (Muller 
HK. et al. 2006). 
After confirmation of a native SCAMP2/SERT complex in glutathione S-transferase pull-
down assays, these investigators documented a decreased Vmax of 5-HT transport when 
SCAMP2 and SERT were coexpressed in transfected cells. This change was paralleled by 
reduced transporter surface expression. SCAMP2 localizes to lipid rafts where, as noted 
above, SERT is also localized. Possibly, SCAMP2 binding could facilitate exit of SERT 
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from lipid rafts to achieve endocytosis of SERT and a reduction in SERT activity. How 
SCAMP2 associations are established or are modulated and how this interaction relates to 
other SERT amino-terminal associations, such as that of Syn1A, are unknown. 
Chanrion et al. (Chanrion B. et al 2007) recently identified a carboxy-terminal association 
of SERT with neuronal nitric oxide synthase (nNOS or NOS1). Cotransfection of yellow 
fluorescent protein-tagged SERT and nNOS leads to reduced 5-HT transport ascribed to 
lower surface expression. Evidence of a functional nNOS/SERT association is evident in 
brain, and synaptosomal 5-HT transport assays using nNOS_/_ mice display increased 
SERT activity and plasma membrane expression. These studies are particularly intriguing 
given evidence, noted below, that a NOS-dependent pathway supports rapid, A3 adenosine 
receptor (A3AR)-dependent elevations of SERT activity, both in mast cells and in 
serotonergic terminals. Possibly, nNOS associations may contribute to entry of SERT into 
an intracellular, regulated pathway. In the absence of nNOS, SERT may remain at the cell 
surface or target the plasma membrane through a constitutive pathway and thus exhibit the 
observed elevations in basal 5-HT transport activity. One expectation arising from this 
hypothesis may be achieved at the expense of regulation of SERT through cyclic GMP 
(cGMP)- and protein kinase G (PKG)-linked pathways. 
Another cell surface receptor whose activation has been linked to acute SERT 
downregulation is the a2 adrenergic receptor (a2AR) (Ansah TA, et al. 2003). Treatment of 
forebrain synaptosomes with 5-bromo-N-[4,5-dihydro-1H-imidazol-2-yl]-6-
quinoxalinamine (UK14304), an a2AR agonist, reduces 5-HT transport, an effect derived 
from a reduced sensitivity to 5-HT (increased Km). UK14304 reductions in 5-HT transport 
were found to be dependent on the activity of voltage-sensitive Caþþ channels, suggesting 
that Caþþ-mediated signaling events downstream of a2AR activation downregulate SERT. 
Chronoamperometry studies documented an ability of acute UK14304 injection to diminish 
5-HT clearance in vivo. These findings support the idea that the well-established adrenergic 
regulation of 5-HT release is accompanied by modulation of 5-HT clearance and suggests 
further consideration of a2AR-directed medications in the pharmacotherapy of mood 
disorders. 
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1.6.1.2 Trafficking-independent modulation 
Ramamoorthy and colleagues made a striking discovery that SERT down regulation by 
PKC activators in platelets is actually biphasic, with both trafficking-dependent and 
trafficking-independent phases of downregulation evident (Jayanthi LD et al 2005). Short 
treatment of rat platelets with PMA leads to rapid inhibition of SERT activity through 
decreased Vmax and increased Km, yet no change in surface expression of the transporter 
is observed. In contrast, longer incubations of platelets with PMA produce a further 
reduction in 5-HT transport Vmax that coincides with a reduction in SERT cell surface 
abundance. With short PMA treatments, phosphoamino acid analyses indicate 
phosphorylation of SERT only at Ser residues, whereas longer treatments lead to both Ser 
and Thr phosphorylation. 
Taken together, these studies indicate that PKC activation can influence two sequential 
modes of SERT regulation, one linked to catalytic downregulation and a second to 
transporter endocytosis. Although specific sites of PKC-dependent SERT phosphorylation 
are as yet undefined, Ser and Thr residues in human NET intracellular loop 2 – residues 
conserved in SERT – were identified as necessary for phorbol ester-triggered 
phosphorylation (Jayanthi LD et al. 2005). 
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1.6.2 Rapid Elevations in SERT Activity 
The examples of acute SERT regulation discussed up to this point involve a decrease in 
SERT catalytic activity or diminished cell surface expression. Below, are describe 
examples of rapid upregulation of 5-HT transport and consider how supporting mechanisms 
lend credence to a bidirectional SERT regulatory cycle that is poised to respond to needs 
for both elevated and diminished 5-HT clearance. 
 
1.6.2.1 Trafficking-dependent modulation 
Miller and Hoffman were the first to identify a rapid, receptor-dependent mechanism of 
increasing SERT function in cultured cells (Miller KJ, Hoffman BJ 1994), research 
corroborated and extended to the CNS by Zhu et al. (Zhu CB. et al 2007). When rat 
basophilic leukemia (RBL-2H3) cells, derived from serotonergic mast cells, are treated 
with a broad-spectrum adenosine receptor agonist, 50-N-ethylcarboxamido-adenosine, 5-
HT transport capacity (Vmax) increases. Zhu et al. utilized specific A3AR agonists and 
antagonists and transporter-receptor-cotransfected cells to validate the role of A3ARs in 
this effect. SERT stimulation by A3ARs requires activation of PKG by a phospholipase C, 
Caþþ, NOS and cGMP-dependent mechanism (Zhu CB. et al. 2004a). Miller and Hoffman 
initially ascribed A3AR regulation of SERT to a change in catalytic function because of no 
detectible changes in SERT antagonist binding. Zhu et al. recognized that the latter measure 
might have failed to discriminate SERT trafficking from changes in total SERT protein. 
These investigators opted for membrane impermeant binding conditions using 5-HT 
displacement at 48C and the cocaine analog methyl 3b-(4-iodophenyl) tropane-2b-carboxic 
acid methyl ester (RTI-55) (as well as biotinylation measures in transfected cells) to define 
subcellular pools of SERT. 
These approaches revealed an increase in SERT surface expression following treatment 
with A3AR agonists, 8-BrcGMP or the endogenous cGMP potentiator sildenafil (Zhu CB, 
et al. 2004 a) comparable to the elevations in 5-HT uptake. Use of membrane impermeant 
[2-(trimethylammonium) ethyl]-methanethiosulfonate bromide to inactivate surface SERTs 
prior to A3AR agonist treatments offers evidence that activation of the A3AR–PKG 
pathway results in the recruitment of intracellular SERTs rather than in retention of surface 
transporters (Blakely  et al. 2004). 
Using mouse brain synaptosomes derived from A3AR_/_ mice and chronoamperometry in 
rat brain, Zhu and colleagues further established that A3ARs regulate SERT in the CNS. 
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PKG antagonists, including the PKG1 isoformspecific peptide inhibitor DT-2 
(YGRKKRRQRRRPPLRK5H), block stimulation of SERT by the A3AR agonist N6-(3- 
iodobenzyl)-N-methyl-50 carbamoyladenosine (IB-MECA) in these native models, as in 
RBL-2H3 cells (Zhu CB et al. 2004b). Although these studies with native preparations 
document the presence of a SERT regulatory cycle in serotonergic terminals, other 
preparations are needed to advance our understanding of the specific mechanisms that 
support synaptic transporter localization and function. McDonald et al. (2007) recently 
demonstrated how direct visualization of Caenorhabditis elegans synaptic DAT proteins 
can be achieved using enhanced green fluorescent proteinlabeled transporters expressed in 
transgenic nematodes, taking advantage of the transparency and identified synapses of this 
model system. Studies are currently underway to adapt this framework to investigation of 
the regulation of the C. elegans SERT, MOD-5 (Ranganathan R et al. 2001). 
Stimulation of SERT through a PKG-linked pathway raises the question as to whether 
SERTs are phosphorylated as a consequence of PKG activation. Using metabolic labeling, 
immunoprecipitations and phosphoamino acid analysis of rat midbrain synaptosomes, 
Ramamoorthy et al. documented SERT incorporation of [32P] after 8-Br-cGMP treatments 
specifically on Thr residues (Ramamoorthy S et al 2007). After comprehensive mutagenesis 
of cytosolic Thr residues, Thr276 of human SERT was found to be the only Thr residue 
essential for 8-Br-cGMP stimulation of phosphorylation. Importantly, mutation of this site 
to Ala blocked 8-Br-cGMP stimulation of 5-HT uptake. Future studies are needed to define 
whether PKG directly phosphorylates SERT at Thr276. In contrast to the studies of Zhu et 
al. who had defined a trafficking-dependent mode of regulation sustained by PKG 
activation, Ramamoorthy et al. suggested that PKG activation leads to catalytic activation 
of SERT. Thus, although treatment of synaptosomes with 8-Br-cGMP led to increased 5-
HT transport by an elevation in 5-HT transport capacity (Vmax), no increase in surface 
SERT was detected using cell surface biotinylation approaches. Three differences between 
the works of these two groups may help clarify this issue. First, Zhu et al. predominantly 
used stimulation of SERT by A3ARs, stimulation likely to activate only a limited pool or 
specific isoforms of cellular PKG. 
Use of 8-Br-cGMP as in the Ramamoorthy’s studies to regulate SERT may activate 
additional pools of PKG whose actions could lead to other effects. Second, Zhu et al. 
employed much lower concentrations of 8-Br-cGMP (10 mM) versus that of Ramamoorthy 
et al. (250 mM). Third, although both groups utilize transfected cell models, levels of 
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expression of SERT in the Zhu studies are kept low to match those originally encountered 
in RBL-2H3 cells that express rat SERT from the native SERT promoter. With a 
biochemical end-point in mind, (the isolation of SERT phosphorylation sites) 
Ramamoorthy et al. were compelled to work with SERT in culture models at much higher 
SERT protein levels.  
 
1.6.2.2 Trafficking-independent modulation 
Based on the ability of p38 MAPK to support trafficking independent regulation of NET 
and of PKG to phosphorylate and activate p38 MAPK, Zhu et al. asked whether p38 
MAPK was involved in SERT upregulation that follows A3AR activation. Remarkably, the 
p38 MAPK inhibitor SB203580 blocked fully the increase in SERT activity seen with IB-
MECA, although it did not prevent elevations in SERT surface expression (Blakely RD et 
al 2005). These findings suggest that PKG enhances both surface trafficking of SERT and 
SERT catalytic activity through two distinct pathways. Indeed, it is possible to bypass PKG 
altogether by using direct activators of p38 MAPK, such as anisomycin, which predictably 
increase 5-HT transport. Whereas PKG activation alters SERT transport capacity, p38 
MAPK activation increases 5-HT affinity (Zhu CB et al 2005). One clue to the mechanism 
of this effect may be found in the recent study of Zhang et al. who show that 
phosphorylation at Thr276 after PKG activation produces an altered conformation of TM5 
(Zhang YW et al 2007). This finding leads naturally to the idea that PKC-induced SERT 
catalytic downregulation may derive from phosphorylation of a nearby residue whose 
modification stabilizes a conformation of TM5 that is associated with a low 5-HT transport 
rate and/or prevents PKG-induced phosphorylation at Thr276. Consistent with this idea, 
PKC activation triggers dissociation of PP2Ac from SERT. 
Because p38MAPK activation triggers catalytic activation of SERT and this effect is 
dependent on PP2A activity, PKG may phosphorylate Thr276 of SERT as well as other 
proteins that control SERT trafficking. PKG could then generate a conformation of SERT 
of higher 5-HT affinity as well as activate p38 MAPK, leading to PP2A activation that 
sustains the inhibitory Ser in a dephosphorylated state so that SERT activation is 
unopposed. Conversely, with p38 MAPK inhibited, PP2Ac activation may be insufficient 
to oppose basal inhibitory phosphorylation at this Ser. Such a model could explain the 
actions of inflammatory cytokines such as interleukin-1b and tumor necrosis factora that 
activate p38 MAPK in a PKG-independent manner leading to enhanced SERT activity, 
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without inducing SERT trafficking (Zhu CB et al 2006). By this model, the removal of 
tonic PKC inhibition is all that is needed to elevate SERT catalytic activity. Further 
research is needed to understand how transit of SERT between distinct protein complexes 
or membrane subdomains places SERT in a context for catalytic modulation. 
Samuvel et al. have also suggested that basal p38 MAPK activity supports SERT 
trafficking. Rat brain synaptosomes treated with the p38 MAPK inhibitors SB203580 or 
PD169316 display decreased basal 5-HT transport that coincides with reduced SERT cell 
surface levels. Additionally, p38 MAPK antagonists reduce basal SERT phosphorylation. 
Again, it is likely that p38 MAPK-supported basal trafficking and p38 MAPK-supported 
SERT catalytic activity can be reconciled if one considers the differences in pharmacology 
(activator versus inhibitor), the alternate serotonergic preparations and the timing of drug 
application utilized in various p38 MAPK studies. As Zhu et al. have shown, acute p38 
MAPK activation leading to enhanced catalytic regulation is monitored when p38 MAPK is 
acutely activated, whereas the studies of Samuvel et al. derive from studies where basal p38 
MAPK is inhibited. Possibly, changes in basal SERT phosphorylation observed with p38 
MAPK inhibitors reflect an indirect consequence of reductions in basal surface expression; 
for example, alterations in SERT phosphorylation may lead to PP2Ac association in 
compartments that prepare SERT to recycle back to the plasma membrane. 
Recently, Carneiro et al. described a novel platelet SERT interactor that supports a 
bidirectional regulation of the transporter (Carneiro AM et al 2008). Using platelets derived 
from mice lacking integrin b3 (Itgb3_/_), the authors determined that 5-HT transport is 
severely reduced, although total and plasma membrane SERT expression is unchanged. 
Conversely, aIIb3 activation by immobilized fibrinogen leads to an increase in 5-HT uptake 
without affecting SERT surface expression. These phenomena appear to be supported, in 
part, through direct physical interactions of the SERT carboxy terminus with integrin b3. 
Remarkably, cotransfection of human SERT and a hyperserotonemia- and 
thrombosisassociated integrin b3 variant, Leu33Pro, leads to increased 5-HT uptake as well 
as to enhanced SERT surface expression. These effects may well relate to some of the same 
mechanisms of SERT regulation described above as the impact of the Leu33Pro variant on 
SERT requires active PP2A and p38 MAPK. Because integrin proteins help establish focal 
adhesions, these studies draw additional attention not only to the trafficking pathways 
between cytosolic and plasma membrane for SERTs but also to the movements between 
plasma membrane subdomains as a critical component of SERT regulation. 
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Fig.5: Schematic illustration of SERT regulation. SERT traffics in and out of the plasma membrane 
(PM) where it resides in distinct membrane compartments and recycles through endosomal (END) 
compartments. Various SERT-associated proteins, including Syn1A, PP2A and Hic-5 (among others), 
differentially associate with SERT in distinct compartments where they can influence transporter 
trafficking and/or catalytic function. MDMA, 3,4-methylenedioxymethamphetamine. 
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Chapter 2 
 
2.1 Obesity 
The epidemic of obesity has become pandemic, defined as an epidemic occurring over a 
wide geographic area and affecting an exceptionally high proportion of the population. The 
rise in obesity rates was first noted in the US, but has spread to other industrialized nations 
and it is even now being documented in developing countries. 
Indeed, the global extent of the obesity pandemic was formally recognized by the World 
Health Organization (WHO) in 1997, and worldwide obesity rates are increasing 
dramatically (Caballero B. 2007). Estimates from the WHO indicate that as of 2005, at least 
400 million adults (9.8%) were obese. Unlike most global health concerns, the obesity 
crisis is even more severe in developed nations. From 1960 to 2004, the prevalence of 
obesity in the US has more than doubled among adults from 13.3% to 32.1%, while the 
percentage of Americans overweight during the same period has increased from 44.8% to 
66%, with most of this rise occurring since 1980. Obesity is clinically identified based on 
measurements of body mass index (Mei Z. et al. 2002), but can be generally defined as the 
physiological condition in which excess body fat has accumulated to an extent that can 
negatively affect health. This definition is based on the dramatically enhanced risk for a 
myriad of disease conditions with obesity, including type 2 diabetes, cardiovascular 
disease, gastrointestinal and respiratory difficulties, and many types of cancer (Haslam 
D.W. 2005). Furthermore, obesity is very closely associated with metabolic syndrome, 
which is characterized by a group of metabolic disorders that can include abdominal 
obesity, insulin resistance or glucose intolerance, atherogenic dyslipidemia, elevated blood 
pressure, and increased expression of prothrombotic and proinfiammatory markers (Olufadi 
R. et al. 2008). 
Based on the large body of evidence that strongly indicates that obesity accelerates the 
onset and exaggerates the severity of a myriad of age-related disorders diseases, including 
hypertension (Hubert H.B. et al. 1983) myocardial infarction (Piegas L.S. et al.2003) and 
stroke (Walker S.P.et al. 1996) one could theorize that obesity accelerates age and age-
related pathologies. Thus, it is possible that obesity might synergistically interact with the 
aging process to significantly accelerate the development of age-related disease and speed 
functional declines in large proportions of the US and global 
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population. The clinical significance of this possibility is amplified by observations that 
obesity rates among the elderly may be even higher than in the general population, as 
estimates indicate that 72% of Americans aged 60 and over are overweight with 32.4% 
obese (Wang Y. et al. 2007). Thus, to address this ominous potential public health crisis, it 
is necessary that clinicians and investigators work together to better understand the etiology 
of obesity-induced alterations to overall health in both clinical and experimental settings. 
One especially costly and debilitating deficit of aging is the loss of cognitive function and 
the onset of dementia. All cognitive disorders, including dementia, become more common 
with age. Indeed, it has been estimated that dementia affects as many as 6–10% of people in 
industrialized nations aged 65 or older, 40–60% of whom may have Alzheimer's disease 
[Riedel-Heller S.G. et al. 2001; Wimo A. et al. 2003; Ferri C.P. et al. 2005). Despite it's 
strong association with age, dementia has been proposed as a mainly preventable condition 
with a large number of modifiable risk factors, including obesity, metabolic syndrome, and 
cardiovascular disease (Haan M.N. et al. 2004). In light of the 1 billion overweight and 300 
million obese individuals worldwide (James P.T.et al.2001) a better understanding of the 
degree to which, and the mechanisms by which, obesity affects the brain could not only 
result in significant advances in public health, but could also unmask the pathophysiologic 
processes that might underlie age-related cognitive dysfunction and dementia. 
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2.2 Food intake and Serotonin  
 
It is now clear that monoaminergic neurotransmitters act in conjunction with neuropeptides 
and peripheral hormones to control physiologic states such as hunger, satiation, and satiety. 
Serotonin has a suppressive effect on food intake and body weight Blundell JE. Et al. 1984;  
Leibowitz SF. Et al. 1988). This has been observed in studies of serotonin receptor 
antagonists and other drugs that decrease serotonin’s activity. Injection of serotoninergic 
agents into the PVN (Currie PJ. Et al. 1996; Currie PJ. Et al. 1996; Leibowitz SF. Et al. 
1989). VMH, anterior hypothalamic area (suprachiasmatic nucleus), and DMN decreases 
food intake (Leibowitz SF. et al. 1994). In addition to decreasing food intake, 
serotoninergic serotoninergic stimulation of the PVN enhances energy metabolism 
(Sakaguchi T. et al. 1989). 
Pharmacologic evidence suggests that central serotonin-1B receptor (5-HT1B) mediates the 
feeding-suppressive action of serotoninergic stimulation in the medial hypothalamus 
(Curzon G. et al. 1997) by mediating the satiety-inducing effect of serotonin (Curzon G. 
1990). In rats, 5-HT1B and possibly 5-HT1C/2C are specifically involved in hypophagia, in 
contrast to 5-HT1A, which may mediate hyperphagia (Hutson PH. Et al. 1988; Kennet GA 
et al . 1988; Dourish CT. Et al. 1986). Acute injection of the 5-HT1A agonist flesinoxan 
stimulates eating and increases NPY concentrations in the PVN and ARC (Dryden S. et al 
1996). Further, in autoradiographic analyses of brain sections, dense concentrations of 5-
HT1B and 5-HT1C receptor sites occur in the hypothalamus, in contrast with low 
concentrations of sites for the hyperphagic 5-HT1A receptor (Razos A.et al 1985). Neurons 
expressing 5-HT1B receptor are found in the PVN, ARC, supraoptic nucleus, and 
retrochiasmatic nucleus. Prominent groups of large and medial neurons with different 5-
HT1B expressions are located in the LHA and are distributed in a specific rostrocaudal 
direction. Medium and light staining is observed in neurons of the PVN, VMN, and DMN 
(Makarenko IG et al. 2002). 
As outlined in the previous sections, several experimental studies have consistently shown 
that abnormal hypothalamic serotonin activity contributes to hyperphagia and body weight 
gain. These data suggest that brain neurotransmission may represent a common step at 
which different appetite-related messengers converge. From the clinician’s perspective, this 
hypothesis might yield interesting approaches to effective therapy for disturbed eating 
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behavior. Specifically, the inhibitory effect on food intake of hypothalamic serotonin may 
be exploited to decrease food intake and achieve weight loss in hyperphagic obese patients. 
Although serotoninergic agents have been used to treat hyperphagia, it must be emphasized 
that their side effects may limit their use (Jung RT. 1998). Sibutramine, a molecule that 
enhances serotoninergic and dopaminergic activities, is one pharmacologic therapeutic 
approach to the management of hyperphagia and obesity (Pederson KJ. Et al. 2003). 
Serotoninergic drugs that act on specific serotonin receptors (5-HT1B or 5-HT2C) decrease 
food intake and specifically fat intake. Several drugs that influence serotonin release (e.g., 
fenfluramine and dexfen- fluramine) or serotonin reuptake (e.g., fluoxetine and sertraline) 
have been used in obese patients. 
D-fenfluramine was used at an average dose of 15 mg twice daily and had been shown to 
increase adherence to weight-lowering programs, to double the number of patients losing 
10 kg or more when compared with a fairly efficient placebo plus dietary counseling, and to 
prevent weight regain when continued over a 1-y period. Moreover, significant 
improvement in metabolic risk factors and blood pressure were clearly demonstrated (Guy-
Grand B.1995). However, severe side effects (in particular pulmonary hypertension and 
valvular heart disease) were reported with these antiobesity drugs, leading to the 
withdrawal of the licensed fenfluramine and D-fenfluramine in 1997 (Scheen AJ.et al. 
1999). 
Sibutramine is a combined 5-HT and noradrenaline re-uptake inhibitor and induces marked 
weight loss by affecting food intake and energy expenditure. There is a doserelated 
decrease in body weight, with weight loss up to 11% when it is associated with a low 
caloric diet, and patients lose 15% of weight over a 1-y period. Further, biochemical risk 
factors associated with obesity ameliorate with sibutramine therapy (Nisoli E. et al. 2000). 
However, the most commonly reported adverse effects of sibutramine are headache, 
constipation, and nausea. Adverse effects related to the nervous system include dizziness, 
dry mouth, and insomnia and are reported by more than 5% of patients. Increases in blood 
pressure and heart rate are possible adverse effects that require regular monitoring 
especially in obese hypertensive patients (Nisoli E. et al. 2003). 
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2.3 Obesity and Inflammation  
 
C Reactive Protein (CRP) is an ancient, highly conserved molecule and a member of the 
pentraxin family of proteins (Du Clos TW. et al. 2000). CRP, secreted by the liver in 
response to a variety of inflammatory cytokines, increases rapidly in response to trauma, 
inflammation, and infection and decreases just as rapidly with the resolution of the 
condition. Thus, the measurement of CRP can be used to monitor inflammatory states. 
CRP has a role in the function of the innate immune system. CRP activates complement, 
binds to Fc receptors, and acts as an opsonin for various pathogens. Binding of CRP to Fc 
receptors leads to the generation of proinflammatory cytokines. CRP can recognize altered 
self- and foreign molecules based on pattern recognition. Thus, enhanced levels of CRP can 
be used as a marker of inflammation. 
Cook et al. (Cook DG. Et al. 2000) observed that higher adiposity indicates higher CRP 
levels in children. A strong relation between elevated CRP levels and cardiovascular risk 
factors, fibrinogen, and high-density lipoprotein (HPL) cholesterol has been noted, 
suggesting a role for inflammation throughout life in the development of atherosclerosis 
and cardiovascular disease. Visser et al. (Visser M. et al. 1999) demonstrated that higher 
BMI is associated with higher CRP concentrations in young adults aged 17 to 39 y, thus 
confirming a state of low-grade systemic  inflammation in overweight and obese persons. 
The elevated CRP concentrations can be ascribed to the increased expression of interleukin-
6 (IL-6) in adipose tissue (Crichton MB. et al. 1999; Mohamed-Ali V. et al. 1997) and its 
release into the circulation (Fried Sk et al. 1998).  IL-6 is a proinflammatory cytokine that 
stimulates the production of CRP in the liver (Banks RE. et al. 1995).   
Higher adipose tissue content of IL-6 has been associated with higher serum CRP levels in 
obese subjects (Bastard JP. et al. 1999). This association is strengthened by the observation 
that in transgenic mice IL-6 is absolutely required for the induced expression of CRP 
(Szalai AJ. et al. 1998). CRP induced a three-fold increase in soluble IL-6 receptor (sIL-
6R) production and promoted a loss of membrane-bound IL-6R, (Jones SA. et al. 1999) 
indicating that CRP may affect IL-6-mediated inflammatory events. In several diseases, 
CRP levels correlated with those of sIL-6R (Kyriakou D. et al. 1997; Desgeorges A. et al. 
1997). CRP binds to specific receptors on human neutrophils and diminishes neutrophil 
chemotaxis,( Szalai AJ. et al. 1997) generation of superoxide anion and degranulation by 
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chemoattractants (Kew RR. et al. 1990) CRP prevents neutrophil adhesion to endothelial 
cells (Zouki C. et al. 1997) and inhibits neutrophil recruitment in models of inflammation, 
(Ahmed N. et al. 1996) suggesting that CRP also performs an anti-inflammatory function. 
In overweight and obese subjects, serum levels of tumor necrosis factor-α (TNF-α), serum-
soluble TNF receptor p55 (sTNFRI), and serum-soluble TNF receptor p75 (sTNF-RII) were 
significantly higher than those in lean subjects. 
Both studies (Tsukui S. et al 2000; Zahorska-Markiewicz B. et al. 2000) reported that 
weight reduction or moderate-intensity regular exercise decreases the serum concentrations 
of TNF-α. Tsukui et al. observed that TNF-α, sTNF-RI, and sTNF-RII were negatively 
correlated with HDL cholesterol. Regular exercise decreased BMI, percentage body fat, 
glycosylated hemoglobin, serum TNF-α, sTNF-RI, and sTNF-RII and increased HDL 
cholesterol levels. Exercise-induced change in serum TNF-α was independently correlated 
with changes in glycosylated hemoglobin and serum insulin concentrations. Chu et al. (Chu 
N-F. et al. 2000) observed that men in the highest quintile of plasma leptin weighed more, 
were less physically active, and had higher circulating insulin, C peptide, sTNF-RI, and 
sTNF-RII concentrations than men in the lowest quintile. On further analysis, only 
glycosylated hemoglobin and sTNF-RI were independently and positively associated with 
plasma leptin in men with BMIs of at least 25 kg/m2, suggesting that glucose homeostasis 
and the activity of the TNF system can modulate leptin secretion among overweight men. 
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2.4 Cytokines, Neurotransmitters and Obesity 
 
Since plasma concentrations of IL-6, TNF-α, and CRP are increased in obesity and several 
neurotransmitters can influence food intake, is it possible that there is an interaction 
between cytokines and neurotransmitters? Infection, injury, and inflammation are 
associated with negative energy balance characterized by reduced food intake, weight loss, 
increased thermogenesis, and fever. Administration of bacterial lipopolysaccharide (LPS), a 
potent inducer of cytokines, to animals upregulates leptin gene expression and serum 
protein levels (Sarraf P. et al. 1997; Grunfeld C. et al 1996).  IL-1 and TNF-α increase ob 
mRNA expression and serum leptin concentration in rodents, whereas LPS does not 
increase leptin levels in mice lacking IL-1 (Faggioni R. et al. 1998). Conversely, exogenous 
leptin upregulates phagocytosis and the production of IL-6, IL-12, and TNF-α (Loffreda S. 
et al. 1998). Leptin-deficient mice (ob/ob) and rats that possess a defective leptin receptor 
(fa/fa) exhibited attenuated levels of TNF-α and IL-6 in response to LPS (Loffreda S. et al. 
1998). Luheshi et al. (Luheshi GN. Et al. 1999) showed that leptin directly induces the 
release of IL-1 within the brains of normal rats and mimics the action of IL-1 in the central 
nervous system (CNS), and that its effects on food intake and body temperature are 
mediated by IL-1. IL-1 and IL-6 act as excitatory neuromodulators of gastrointestinal 
motility and caused a presynaptic inhibition of ACh release from cholinergic nerve 
terminals (Kelles A. et al. 2000). These results are interesting because vagus nerve 
stimulation in vivo inhibits TNF synthesis and ACh, the principle vagal neurotransmitter, 
attenuates the release of proinflammatory cytokines TNF, IL-1, IL-6, and IL-18 but not the 
antiinflammatory cytokine IL-10 in LPS-stimulated macrophages (Borovikova LV et al. 
2000). Thus, serotonin, dopamine, NPY, and leptin can influence the synthesis and release 
of proinflammatory cytokines by their ability to alter ACh release in the brain. Hence, ACh 
may be a neurotransmitter and acts as an antiinflammatory molecule in the brain. NO 
participates in inflammation. The inducible type of NO produced by macrophages has 
proinflammatory actions (which is stimulated by TNF-α, IL-1, and IL-6), whereas eNO and 
neuronal NO show antiinflammatory actions. Leptin, by enhancing IL-1 concentrations, 
may possess proinflammatory actions, whereas neurotransmitters such as serotonin, 
dopamine, and NPY show antiinflammatory actions by inducing ACh release, which in turn 
 31 
suppresses the production of proinflammatory cytokines (Borovikova LV et al. 2000). This 
is supported by the observation that dopamine attenuates the chemoattractant effect of IL-8 
(Sookhai S. et al. 2000). This interaction between neurotransmitters and cytokines is 
supported by the work of Cho et al. (Cho L. et al 1999) who showed that endotoxin and 
TNF can alter the metabolism of norepinephrine and the concentrations of serotonin and 
dopamine in the hypothalamus. 
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Chapter 3 
 
3.1 Introduction  
Several studies have shown the involvement of the serotonergic transmission and of the 
serotonin in the eating behaviour and body weight in humans (Leibowitz S.F. et al 1998; 
McElroy S.L. et al. 2000; Wolfe B.E. et al. 2000). In general, treatments and procedures 
believed to activate 5-HT receptors reduce food intake consumption, on the contrary 
procedures which, either directly or indirectly, decrease 5-HT receptor activation bring 
about the opposite effect. Patients with bulimia nervosa have been shown to have lower 
cerebrospinal fluid concentrations of the 5-HT and their metabolites than healthy controls 
(Jimerson D.C. et al 1992). Serotonergic receptor responsiveness seems also to be impaired 
in bulimic patients (Brewerton T.D 1995). In addiction, selective serotonin re-uptake 
inhibitors have been shown to be effective in the treatment of bulimia nervosa (Rissanen A. 
et al. 1998). Moreover, alterations in the 5-HT system has been demonstrated in binge 
eating disorder (BED) (Kaye W. et al. 1998). It is recent the ability to label "in vivo" 5-HT 
transporter in BED (Kuikka J.T. et al. 2001). Single-photon emission tomography (SPECT) 
imaging with a ligand specific for SERT, shows a significantly decreased SERT binding in 
the mid-brain of obese BED women, thus providing evidence that diminished serotonergic 
activity could be involved in this eating behaviours. The contribution of the 5-HT system 
to obesity induced in normal rats by feeding a palatable diet has been investigated by 
measuring the density of binding to the main 5-HT receptor subtypes implicated in feeding 
(5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C) and to SERT using quantitative autoradiography of 
midbrain and hypothalamic sections (Park S. et al 1999). It has been speculated that 
sustained changes in 5-HT neuronal activity would lead to reciprocal alterations in binding 
to the specific 5-HT receptor subtypes involved, consistent with observations that 
increased or decreased 5-HT release leads to fewer or greater 5-HT binding sites, 
respectively (Casanovas J.M. et al. 1999). Recently, a serotonergic marker of night eating 
syndrome (NES) has been implicated with the recently discovered therapeutic response to 
the selective serotonin reuptake inhibitor, sertraline. A SPECT study compared the 
serotonin transporter (SERT) uptake ratios, using the radiopharmaceutical (123)I-ADAM, 
in midbrain, basal ganglia, and temporal lobes of night eaters with those of healthy 
controls. Night eaters had significantly greater SERT uptake ratios in the midbrain than 
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healthy controls. These findings, in conjunction with the therapeutic response of NES to 
sertraline, indicate that the serotonin system is involved in the pathophysiology of NES 
(Lundgren JD. Et al. 2008). Moreover, Bruce KR et al. (Bruce KR et al. 2006) showed that 
women with anorexia nervosa (AN) had significantly lower levels of platelet paroxetine 
binding compared with control group. Simple correlation analyses showed that, within AN 
but not within controls, paroxetine binding was inversely related to dieting preoccupations, 
affective instability, anxiousness, compulsivity, restricted expression and social avoidance 
but independent of age, body mass index, depression, and other eating symptoms. Findings 
suggest that reduced peripheral serotonin transporter density in AN relates to increased 
dieting preoccupations, affective instability and anxiousness–fearfulness.  
It appeared interesting to evaluate SERT expression in obese patients and in normalweight 
subjects. Since it is difficult to directly study the 5-HT function in the brain of living 
human, we used circulating cells. Platelets are terminally differentiated cells that exhibiting 
SERT presence, rapid phosphorilation upon agonist-induced activation and represent a 
good model system to study signal transduction events (Aharanovitz O. et al. 1999; Lesch 
K.P. et al. 1993). Moreover, they have been widely used in biological studies on 
psychiatric disorders, for the investigation of neuronal serotonergic system (Marazziti D. et 
al. 1998; Stahl S.M. 1997).  
Obtained binding data of all subjects were statistically correlated with relative clinical 
parameters (as glucose, leptinemia, TNF-α, insulinemia). 
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3.2 Materials and Methods 
3.2.1 Subjects 
 
174 individuals, matched for age and sex, whose had no history of psychological 
disturbance or behavioral disorder of eating or drinking were recruited from Department of 
Endocrinology and Metabolic disorders of University Division, Cisanello Hospital, Pisa. 
The degree of obesity was estimated by body mass index (BMI) and all subjects were  
classified using the following values: 
 
 Obesity class III°  (BMI > 40 kg/m2) 
 Obesity class II°   (BMI > 35 kg/ m
2
) 
 Obesity class  I°    (BMI  between 30 and 35 kg/ m
2
) 
  Overweight          (BMI between 25 and 29,9 kg/ m
2
) 
  Normal weight     (BMI  between 18,5 and 25 kg/ m
2
) 
 
Each class was comparable for number of subjects.  
Prior screening verified the absence of co-morbid disease, including infection, 
inflammatory disease, underlining neuroendocrine abnormality, or cancer. Subjects with 
hypertension, cardiac dysrhythmias, hypercholesterolemia, hypertriglyceridemia, and 
diabetes mellitus were excluded.  
 
The inclusion criteria for the study groups comprised a negative history for psychoactive 
drug treatment and other neurological disorders. None of the subjects had co-morbid 
psychiatric disorders or had received treatment with antidepressant drugs. No patient was 
under pharmacological treatment.  
To exclude major psychiatric disorders, all patients were evaluated by means of a 
diagnostic interview consisting of the administration of the Structured Clinical Interview 
for DSM-IV axis-I disorder (SCID-I/P). This assessment was conducted by psychiatrists 
who were trained and certified in the use of the study instruments at our department. 
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All subjects gave their informed consent to participation in the study which was approved 
by the Ethics Committee of Pisa University. 
3.2.2 Clinical and anthropometric parameters evaluation 
 
All subjects were submitted to clinical (blood levels of leptin, insulin, glucose, cytokines, 
cholesterol) and anthropometrics parameters evaluation. 
 
3.2.3 Platelet separation 
 
Venous blood (30ml) was drawn from fasting subjects between 8 and 10 a.m., collected 
into plastic tubes containing 5 ml of anticoagulant (2.2% sodium citrate and 1.2% citric 
acid) and centrifuged at 150 xg for 15 min at 23 °C. Platelet-rich-plasma was collected and 
centrifuged at 1500 xg for 15 min at 23 °C. Platelets were counted automatically with a flux 
cytometer (Cell-dyn 3500 system; Abbott, Milano, Italy). 
For measurement of [3H]serotonin reuptake, platelets were used immediately, whereas for 
[3H]paroxetine binding, platelets were precipitated by centrifugation at 10,000g for 10 
minutes at 4°C and the pellets were then stored at -80°C until the assay. 
 
 
3.2.4 Membrane preparation for binding assay 
Platelet pellets were suspended in buffer (5 mM Tris–HCl, pH 7.4) containing protease 
inhibitors Benzamidine 160µg/ml, Bacitracine 200µg/ml and Tripsine inhibitor 20µg/ml, 
homogenized using an Ultraturrax homogenizer and centrifuged at 48 000xg for 15 min at 4 
°C. The ensuing pellet was washed with buffer (50 mM Tris–HCl, pH 7.4) and treated as 
described above. The resulting pellets were suspended in assay buffer (50 mM Tris-HCl, 
120 mM NaCl, 5 mM KCl, pH 7.4) and homogenized using Ultraturrax. Protein content 
was determined by Bredford method (Bio-rad), using γ-globuline as standard. 
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3.2.5 [
3
H]Paroxetine binding assay 
The [
3
H]-paroxetine (PerkinElmer, A.S. 21.3Ci/mmol) binding was carried out   incubating 
100 µl of membranes (50–100 µg proteins/tube) mixture consisted with 50 µl of [
3
H]-
paroxetine at five concentrations ranging from 0.08 nM to 1.5 nM, and 1850 µl of assay 
buffer. Specific binding was obtained as the binding remaining in the presence of 10 µM 
fluoxetine as a displacer. All samples were assayed in duplicate and incubated at 22 °C for 
1 h. The incubation was halted while adding 5 ml of cold assay buffer and simples were 
treated as previously described. 
 
 
3.2.6 [
3
H]5-HT  re-uptake  
Platelet 5-HT uptake assays were carried out on intact platelets from all subjects. 
Platelets were maintained under physiological conditions, such as isotonic buffer, 
presence of NaCl and glucose, 37°C assay temperature.  
After separation, platelets in PRP were counted automatically through a cytofluorimeter. 
Serotonin uptake was carried out by incubating for 10 min. at 37°C aliquots of a cellular 
suspension (2x10
6
 platelets) with crescent concentrations of [
3
H]-5-HT (range: 40nM-
1200nM) in a Krebs assay buffer, containing: 118mM NaCl; 4.7mM KCl; 1.07mM 
Mg2SO4⋅7H2O; 1.17mM KH2PO4; 25mM NaHCO3; 11.6mM glucose; pH=7.4. The final 
assay volume was 0.5ml.  
For each concentration of [3H]-5-HT, non specific uptake was measured by adding 
10µM unlabelled fluoxetine. After incubation, the radioactivity present inside cells was 
separated from the free amount by means of a rapid filtration on Whatman GF/C filters 
by Brandel, and three washes were subsequently carried out (5ml each). Filters were 
incubated for 5 min in vials containing 200 µl 0.2N NaOH to break platelets and after 
neutralized by adding 200 µl 0.2N glacial acetic acid. Finally, radioactivity was counted 
through a liquid phase scintillation β-counter  Packard 1600 TR and taken as dpm. The 
specific uptake was calculated from the difference between total and non specific 
uptake.  
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3.2.7 Data analysis 
 
Equilibrium-saturation binding data, the maximum binding capacity (Bmax, fmol/mg of 
protein) and the dissociation constant (Kd, nM) were analysed by means of the iterative 
curve-fitting computer programs EBDA and LIGAND (Kell for Windows, v. 6.0). For 5-
HT uptake experiments, the specific uptake obtained at the different radiolabeled 
neurotransmitter concentrations were converted into pmol (picomoles) of 5-HT/109 
platelets/min and data elaborated by means of the Michaelis-Menten equation. 
Statistical analysis was conducted using Graph-Pad Prism 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 38 
3.3 Results 
 
3.3.1 [3H]Paroxetine binding assay 
 
Saturation and Scatchard specific binding analysis of [
3
H]-paroxetine revealed a single 
population of high affinity sites in platelet membranes from all subjects under investigation. 
The specific binding represented about the 90% of total binding at the Kd concentration. 
Table 1 shows the mean of Bmax values for the density, and Kd values for the affinity, of 
[3H]paroxetine binding on platelet SERT in all subjects including in this study.  
 
Subjects Bmax (fmol/mg proteins) 
(mean±S. D.) 
Kd (nM) 
(mean± S. D.) 
Normalweight 1443,8±242,55 0,088±0,032 
Overweight 1340,2±203,42 0,076±0,049 
Obesity Class I 891,315±133,72*§ 0,047±0,006 
Obesity Class II 925,233±362,52*§ 0,068±0,022 
Obesity Class III 926,860±261,53*§ 0,071±0,039 
 
              Table 1:    Kinetic parameters (Bmax and Kd) of [3H]paroxetine binding in platelets from the 
populations under study. Data are presented as mean ± SEM of experiments each performed in 
duplicate. (*p<0,05 vs normalweight; § p<0,05 vs overweight)       
 
Data showed a reduction of SERT density with respect to increasing body weight. By mean 
of t-test of Student for unpaired data, a significant reduction of platelet [
3
H]-paroxetine 
Bmax in obesity classes vs. subjects with normal BMI is revealed. Moreover a significant 
reduction of Bmax values was showed between obesity classes vs overweight subjects. 
Age, sex and smoke did not seem to influence the binding parameters of platelet SERT in 
either normalweight and overweight or obese subjects. 
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In figure 1, the linear regression analysis between BMI and SERT Bmax considering all 
subjects introduced into the study is shown: there is an inverse significant correlation 
between BMI and [
3
H]-paroxetine Bmax as fmol/mg protein (***significant,  p <0,0001). 
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      Fig.1 Linear regression between BMI and Bmax values   (p <  0,0001) 
 
 
Moreover, several important positive correlations was evidenced between BMI and 
several clinical serum parameters. Consequently negative correlations was evidenced 
between Bmax and the same clinical data (Table  2). 
 
 
Table 2: Statistical correlations between clinical parameters and BMI or Bmax values 
 TNF-α 
Aptoglobin 
 
Leptin 
 
PAS 
 
Glicemia 
 
Insulin 
 
Triglicerids 
 
BMI 
 (positive 
correlations) 
p<0.0001 p<0.0001 p<0.0001 p<0.0001 p=0.0088 P=0.0003 
 
p=0.0125 
 
Bmax 
(negative 
vorrelations) 
p<0.001 p=0.0277 p=0.0003 p=0.065 p=0.00034 p<0.001 p=0.0147 
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3.3.2 [3H]5-HT up-take assay 
 
Table 3 displays the mean ± S.E.M of maximal velocity, Vmax, expressed as 
pmol/10
9
plt/min, and the Michaelis-Menten, Km, expressed in nM, of the [
3
H]-5-HT 
uptake site in platelets from the sub-groups of subjects under investigation.  
Neither a significant reduction of 5-HT uptake Vmax, was observed in any group, nor a 
significant correlation between BMI and Vmax was reported. Similarly to Kd, Km did not 
significantly differ with respect to body weight.  
 
 
 
 
 
 
 
 
 
 
Table 3 Kinetic parameters (Vmax and Km) of 5-HT uptake in platelets from the populations 
under study. Data are presented as mean ± SEM of experiments each performed in duplicate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subjects 
Vmax 
(pmol/10
9
plt/min) 
Km  
(nM) 
Normalweight 134,5±16,86 194,8±46,65 
Overweight 156,1±22,56 114,5±14,56 
Obesity Class I 152.1±23.20 196,1±17,53 
Obesity Class II 150.3±20.12 190.2±15.62 
Obesity Class III 107.8±15.45 184,1±40,53 
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     3.4 Discussion 
 
Amongst molecules active in modulating 5-HT transmission, SERT exerts a main 
function by promoting 5-HT clearance and re-uptake into the pre-synaptic terminal, 
therefore controlling either the duration and extent of the transmitter action at specific 
targets after release or its “reserve” inside pre-synaptic vesicles. For this reason, 
SERT expression and function is under the control of several intracellular 
phosphorylation systems (Ramamoorthy et al. 2007). More recently, a relationship 
between obesity and inflammatory-immune response has been suggested (Matarese 
and La Cava, 2004), indicating a cross-talk between CNS and periphery in the control 
of body weight. In a preliminary attempt to elucidate these networks, the present 
study was thus designed to investigate the influence of 5-HT on body weight by 
measuring the equilibrium binding parameters (maximal binding capacity, Bmax and 
dissociation constant, Kd) of the high affinity SERT ligand [
3
H]-paroxetine in 
platelets from 174 subjects recruited on the basis of their body mass index (BMI), 
starting from 18 to  > 40 kg/m2. The high affinity ligand [3H]-paroxetine was used as 
a selective tracer of SERT and subjects recruited to obtain five groups as regards to 
BMI: 1. normal weight (18-25 kg/ m
2
), 2. overweight (26-30 kg/ m
2
), 3. obese, I 
grade, (31-35 kg/ m
2
), 4. obese, II grade, (36-40 kg/ m
2
); 5. obese, III grade, (>40 kg/ 
m
2
). All subjects were also accurately monitored for clinical-biochemical parameters, 
including insulinemia and leptinemia blood glucose, insulin, leptin cytokines and 
other clinical-chemical parameters. We have chosen to study platelets as these non 
nucleate cells display an identical SERT to the brain one as well as several 5-HT 
receptor subtypes. For such reasons, platelets are considered “indicators” of 5-HT-
regulated CNS-periphery connections and have been extensively studied in 
psychiatric-affective disorders since many years (Mellerup et al, 1983; Martini C. et 
al., 2004). Finally, platelets respond to agonist-induced activation by rapid 
phosphorilation and represent, therefore, a good model to study neuronal signal 
transduction events in periphery (Aharanovitz and Granot, 1996 ).  
Our study is the first that showed a significant reduced SERT density in platelets of obese 
subjects (p<0.05), providing new insights in the role of 5-HT system and obesity. 
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Moreover, no BMI-dependent changes in [3H]-paroxetine Kd (nM) values, but a 
significant inverse correlation (p<0,0001) between [3H]-paroxetine Bmax values 
(fmol/mg protein) and BMI. 
Consequently, a negative significant correlation was observed between [3H]-paroxetine 
Bmax values and: blood leptin, TNF-α, insulin, glicemia, PAS, aptoblobin and 
triglycerides.  
In conclusion, these findings show that platelet SERT number is reduced in obese 
subjects and such a decrease could be linked, in part, to the efficiency of the 
insulin/adipokine-related downstream signaling cascade in periphery. These results could 
explain that adipose tissue entity are able to modulate SERT expression, but not his 
functionality, in platelets membrane. 
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Chapter 4 
 
4.1 Introduction 
 
The serotonergic system is involved in the energetic homeostasis regulation and its 
activation tends to produce a negative energetic imbalance, mean an inhibition of food 
intake and an higher caloric expenditure. Moreover, adipocytes produce different factors 
which are able to regulate appetite, thermogenesis and insulin sensitivity. It is unknown 
how the serotonergic system is integrated with other pathways involved in energetic 
metabolism control, and in particular if it is regulated by adipose depots entity. 
Our laboratory showed a reverse correlation between the body mass index (BMI) of obese 
and lean subjects and Bmax (maximal density) values of serotonin transporter (SERT) 
obtained in [3H]paroxetine binding assays. These results could explain that adipose tissue 
entity are able to modulate SERT expression in platelets membrane. After that, our results 
showed a significant correlation between Bmax values and serum concentrations of 
different factors, which values are greater in obese subjects, as inflammation markers. 
 
 
Identification of isolated cellular model, capable to express SERT and having biochemical 
characteristics of platelet, could be useful to study the modulation of serotonin transporter 
by different factors related with obesity. We identified this model in MEG-01, a human 
megakaryoblastic leukaemia cell line, which specifically retains the morphological and 
functional properties of bone marrow megakaryocytes. This cell line is considered to be the 
most suitable one for evaluating human megakaryocytic maturation and differentiation into 
platelet-like cells (Isakari Y. et al 2007). 
Literature studies reveal that MEG-01 cells mantain the capacity to differentiate 
morphologically, ultrastructurally and biochemically into more mature megakaryocytes 
through phorbol esters (β-TPA) stimulation (Yang M. et al 1996). 
A first aim of this research project was to evaluate serotonin transporter (SERT) expression 
in Meg-01 cell line, before and after treatment with β-TPA, using  monodimensional 
electrophoresis, quantitative real-time PCR and immunofluorescence technique. Moreover 
we evaluated SERT functionality by mean of radiolabeled 5-HT up-take. 
 44 
4.2 Material and Methods 
 
4.2.1 Cell culture and treatment 
 
The human megakaryoblastic cell line MEG-01 was purchased by LGC Promochem 
(American Type Culture Collection (ATCC),VA, USA- Milan, Italy). 
MEG-01 cells were seeded (2x105 cells) on T-75 ventilated cap flasks (Sarsted,Verona,  
Italy) in modified RPMI 1640 medium (LGC Promochem), containing 0.3g/liter L-
glutamine (LGC Promochem), supplemented with 10% fetal bovine serum, FBS (LGC 
Promochem), antibiotics (100 U/ml penicylline and 100 mg/ml streptomycine, LGC 
Promochem). Cells were cultured inside a humidified incubator at a temperature of 37°C 
under an atmosphere of 5% CO2. Each 3-4 days the spent medium was diluted with fresh 
medium after centrifugation of cells at 1100 g for 5 min at room temperature. MEG-01 
passages and sub-cultures were carried out in 10- cm dishes (Sarsted) for about 10-12 days 
after seeding. Cell mortality was tested by the Trypan blue dye test. Between passages 3-4, 
when they were usually in good growth, showing a low cell mortality (2-5%) and low rate 
of spontaneous differentiation, cells were divided in two different sub-cultures: 1) control 
MEG-01 cells, allowed to grow in usual RPMI medium; 2) treated MEG-01 cells, cultured 
in RPMI medium supplemented with 10-7M β-TPA (4-β-12-tetradecanoylphorbol-13-
acetate/Phorbol 12-Myristate 13-acetate; Sigma-Aldrich, P1585, Milan, Italy). Since β-TPA 
is dissolved in ethanol (EtOH), control cells were treated with EtOH vehicle. Control and 
treated sub-cultures were carried out by changing medium as above described, except for 
SERT mRNA expression experiments, where cells were maintained in culture for 3 day 
only: in fact, in pilot experiments, after 3 days of β-TPA exposure, SERT mRNA 
transcription reached a steady state plateau. 
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4.2.2 SERT Western Blot analysis 
 
For Western blot analysis, both control and treated MEG-01 cells were harvested and 
centrifuged at 1000 g for 25 min at room temperature. Pellets were solubilized n lysis 
buffer: 25mM HEPES, 0.44% sodium-dodecyl sulfate (SDS, Sigma- ldrich), 1% Triton 
X100, 111 mM NaCl, 2.2mM EDTA, Protease Inhibitor ocktail (Sigma-Aldrich) pH 7.4, 
sonicated and centrifuged at 12 000 g for 20min. 
Total protein amount in soluble fractions was estimated using the Bio-Rad RC/DC rotein 
assay, using bovine serum albumin (BSA) as the standard. Sample aliquots were mixed to 
SDS-reducing buffer (Laemmli 2X: 1.25 ml 0.5 m Tris-HCl, pH 6.8, .15 ml 20% SDS, 0.5 
ml β-mercaptoethanol (Sigma-Aldrich), 1 ml glycerol, 6.1 ml 2O, 2 mg bromophenol blue 
(Sigma-Aldrich) and boiled for 3min. 50µg of sample and standard proteins (Precision Plus 
Protein Standards, Biorad, 161-0373) were then loaded into a SDS-PAGE 10% 
polyacrylamide gel and separated by electrophoresis (16 mA for the first 15 min; 30 mA for 
about 1h.30 min) in running buffer (25 mM trizma base, 192 mM glycine, 0,1% SDS) at 
4°C. Electrophoresis was carried out in a dual Mini vertical gel system (Biorad): one gel 
was blue-Comassie stained for band visualization, the other one was electroblotted (25V for 
2hours) into a 0.2 µm nitrocellulose paper. The nitrocellulose blotted membrane was then 
incubated in a PBS-milk solution (10 mM NaH2PO4, 0.9% NaCl pH 7.5, 3% milk, 0.2% 
Tween) for 60 min under agitation; afterward, nitrocellulose was incubated for 2 hours at 4 
°C under agitation in PBS-milk solution containing the anti-SERT rabbit polyclonal first 
antibody (1:400 diluted) (Chemicon, AB9322). 
Nitrocellulose was then washed 4 times in PBS-milk and incubated in PBS-milk with a 
peroxidase-labelled goat anti-rabbit secondary antibody (1:20 000; Santa Cruz) for 1 hour 
at room temperature. For specific SERT band visualization, nitrocellulose was incubated 
with a solution containing Luminol (ECL kit, Amersham) for 1 min and exposed to a 
Kodak Biomax ML film for 30 min. SERT band signal intensity in control and treated cells 
was analyzed by a densitometry program (Image J). 
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 4.2.3 Isolation of RNA and PCR of SERT m-RNA 
 
Total RNA was isolated from MEG-01 cells with an extraction  kit (Tripure, Roche 
Molecular Biochemicals) and its integrity was evaluated by formaldehyde agarose gel 
electrophoresis. RNA was treated with Rnase-free Dnase (Roche Molecular 
Biochemicals) to remove any contaminating genomic DNA. First-strand cDNA 
synthesis was performed using Superscript III reverse transcritase (Invitrogen) and 
random oligo hexamers (Pharmacia), following manufacturer instructions. SERT 
expression in control and treated MEG-01 cells was evaluated by TaqMan (Applied 
Biosystems 7700) quantitative Real Time PCR. In detail, 50 ng of cDNA were 
amplified with TaqMan Universal PCR Master Mix (Applied Biosystems, Branchburg, 
New Jersey USA) using specific oligos and probes commercially available from 
Applied Biosystems (SERT: HS00169010_m1). The relative abundance of mRNA was 
calculated using the TATA Binding Protein (TBP) mRNA as the invariant control 
(TBP: HS0042760_m1).  
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 4.2.4 Immunofluorescence/bis-benzimide labeling  
 
MEG-01 cells (2x10
5
 cells/well) were seeded in BD-BIOCOAT poly D-lysine cellwares 
(8 well culture slides: BD BIOSCIENCE). Treated and control Meg-01 cells were 
rinsed with PBS 0.1 M buffer (81 mM NaH2PO4, 19 mM Na2HPO4, 0.9 % NaCl, 
pH=7.4), fixed in paraformaldehyde solution (4% in PBS) at room temperature (RT) for 
15 min and then washed three times with PBS for 5 min. Non-specific site blocking and 
cell permeabilization was performed by incubating cells in a PBS solution containing 
1% bovine serum albumin (BSA) and 0.1% Triton X-100 at RT for 30 min. Cells were 
then incubated at 4 °C with the first antibody, specific for the 516-630 amino acidic C-
terminal region of SERT (rabbit anti SERT polyclonal  antibody, Chemicon, AB9322), 
1: 1000 diluted in PBS containing 1% BSA and 0.01% Triton X-100. Cells were then 
washed three times with PBS and incubated at RT for 2 hr with a 1:200 diluted Alexa 
Fluor 488 (Goat Anti rabbit IgG (H+L), Molecular Probes, A11008) fluorescein 
isothiocyanate (FITCH) labeled secondary antibody.  
After PBS washing, cells were mounted in Vectashield (Vector Laboratories) medium. 
To improve signal visualization, cells were also labeled with the nuclear labelling bis-
Benzimide (Hoechst 33258, Sigma) 1:10 000 dilution in PBS at RT for 2 min. Cell 
fluorescent signal (λex.=495 nm and λem.=519 nm) was viewed using a Zeiss 
Axioskop microscope (Carl Zeiss GmbH, Jena, Germany). Digital images were taken 
by a Leica DC100 camera (Leica, Wetzlar, Germany). The brightness and contrast of 
final images were analyzed by means of Adobe Photoshop version 6.00 (Adobe 
Systems, Mountain View, CA). 
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 4.2.5 Measurement of 5-HT up-take 
[
3
H]-5-HT re-uptake was measured in control and β-TPA-treated MEG-01 cells 
according to a slightly modified procedure from Arora and Meltzer (1981): aliquots of 
cells (0.2mg of proteins/assay tube) were incubated for 10 min at 37 °C with [
3
H]-5-HT 
(Perkin Elmer Life Science, Milan, Italy; specific radioactivity: 28.1 Ci/mmol) at six 
concentrations (0.1-10 µM) in 0.5 ml (final volume) of assay buffer (Krebs buffer, 
KHP) composed by 118 mM NaCl, 4.7 mM KCl, 1.07 mM MgSO4.7H2O, 1.17 mM 
KH2PO4, 25 mM NaHCO3, 11.6 mM glucose, pH 7.4, in the presence of 0.1 % 
ascorbate and 100 µM pargyline. Non-specific uptake was measured in the presence of 
10 µM fluoxetine. SERT velocity was stopped by ice-cold KHP buffer and rapid 
filtration through Whatman GF/C filters, using a Brandel cell harvester apparatus. 
Filters were then washed three times with assay buffer, put into a vial  containing 4 ml 
scintillation cocktail liquid (UltimaGold, Packard), shacked and measured by means of 
a β-counter (Perkin Elmer Tricarb 2800TR). SERT velocity was calculated as pmol 5-
HT /mg protein/10 min, using the Eadie-Hofstee linear regression analysis. Total 
protein assay was carried out following the procedure of  Bradford (Bradford 1976).  
 
 
4.2.6 Membrane preparation for binding assay 
Cells were harvested, precipitated and centrifuged at 1000xg for 10 min at RT. Pellets were 
suspended in buffer (5 mM Tris–HCl, pH 7.4) containing protease inhibitors Benzamidine 
160µg/ml, Bacitracine 200µg/ml and Tripsine inhibitor 20µg/ml, homogenized using an 
Ultraturrax homogenizer and centrifuged at 48 000xg for 15 min at 4 °C. The ensuing pellet 
was washed with buffer (50 mM Tris–HCl, pH 7.4) and treated as described above. The 
resulting pellets were suspended in assay buffer (50 mM Tris-HCl, 120 mM NaCl, 5 mM 
KCl, pH 7.4) and homogenized using Ultraturrax. Protein content was determined by 
Bredford method (Bio-rad), using γ-globuline as standard. 
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4.2.7 [
3
H]Paroxetine binding assay 
The incubation mixture consisted of 100 µl of membranes (100-200 µg proteins/tube), 50 
µl of [
3
H]-paroxetine at five concentrations ranging from 0.08 nM to 1.5 nM, and 1850 µl 
of assay buffer. Specific binding was obtained as the binding remaining in the presence of 
10 µM fluoxetine (Tocris) as a displacer. All samples were assayed in duplicate and 
incubated at 22 °C for 1 h. The incubation was halted while adding 5 ml of cold assay 
buffer. The content of the tubes was immediately filtered under vacuum, through glass fiber 
filters GF/C (Whatman) 2.5 cm in diameter and washed three times with 5 ml of ice-cold 
assay buffer. Equilibrium-saturation binding data, the maximum binding capacity (Bmax 
fmol/mg) and dissociation constant (Kd, nM), were analysed by means of the iterative 
curve-fitting computer program (Kell Radlig, version 6) 
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4.3 RESULTS 
4.3.1 SERT Western blot analysis in β−TPA-treated and control MEG-01 
cells 
 
As shown in Figure 1A , Western blot produced a single SERT band with an apparent 
molecular weight of 71 KDa in both treated or untreated cells; the figure also depicts the 
semi-quantitative comparison of SERT band signals by densitometry, revealing 
significantly higher mean optical density values (t-test, P=0.0416) in 8 day β-TPAtreated 
(8743 ± 886, mean ± S.E.M., O.D. arbitrary units) vs. control (5694 ± 527, mean ± S.E.M., 
O.D. arbitrary units) MEG-01 cells, corresponding to an about 1.5 fold increase of SERT 
protein (Figure 1B). After 3 day of β-TPA treatment, no difference in SERT band optical 
density was instead observed between control and treated cells (data not showed). 
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Fig.1 Western Blot (A) and SERT protein levels (B) 
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4.3.2 SERT mRNA transcription is enhanced in β-TPA-treated MEG-01 
cells 
 
After MEG-01 cell treatment by β-TPA for 3 days, real time PCR revealed a threefold 
increase of SERT mRNA concentration in treated vs. control cells. SERT mRNA levels 
(n=10, independent experiments) are represented in Fig. 2, expressed as relative measure to 
the housekeeping gene transcript, TBP. Statistical analysis resulted in a highly significant 
greater amount (t-test, p<0.0001) of SERT mRNA in treated cells (0.911 ± 0.013, mean 
± S.E.M., relative SERT mRNA) vs. control (0.346 ± 0.028, mean ± S.E.M., relative SERT 
mRNA).   
 
 
 
 
 
 
                                                        Fig. 2: SERT mRNA levels 
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4.3.3  β-TPA-treated MEG-01 cells show a different SERT 
immunofluorescence pattern 
 
After cell exposure to 10-7 M β-TPA in 10% FBS for 8 days, significant MEG-01 
morphological changes were observed in culture flasks by inverse microscopy: 
megakaryoblasts increased in size, became adherent and emitted cytoplasm extrusions 
(blebs): about 70-80% of total alive MEG-01 cells presented cytoplasm blebs (Figures 3). 
Figure 4 shows double-labeled (green SERT/blue DNA-specific dye) MEG-01 cells, 
control (4a) vs. 8 day β-TPA-treated cells (4b,c,d). Fluorescence microscopy observation of 
undifferentiated cells reveals specific SERT signals, clearly indicating that megakaryoblasts 
express SERT. A more differentiated megakaryoblast is also visible, showing a greater 
cytoplasm with a more diffuse fluorescence (see arrow, Figure 4a). After 8 days of culture 
with β-TPA, morphological changes were paralled by a greater and diffuse fluorescence 
pattern of SERT protein, distributed in correspondence of either cell bodies or blebs, as 
shown by arrows in Figure 4b,c,d. 
 
 
 
             
 
Fig 3:  Meg-01 control and Meg-01 after treatment with 10-7 M β-TPA 
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Fig.4 Meg-01 Immunofluorescence  
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4.3.4 Comparison of [3H]-serotonin uptake in β−TPA-treated and control 
MEG-01 cells 
 
 
Table 1 reports SERT functional kinetic parameters, the Michaelis-Menten constant, Km 
(µM), and the maximal 5-HT uptake velocity, Vmax, in treated and control MEG-01 cells. 
The mean SERT Vmax in 8 day β-TPA exposed cells resulted about 1.37-fold higher than 
that observed in control cells, without reaching however the statistical  (t-test, p=1609). Km 
uptake values resulted unchanged in β- TPA-treated MEG-01 cells vs. controls. 
 
 
 
Km 
(µM) 
 
Vmax 
(pmol/mg protein/10min) 
 
Control n=3 0.51 ±0.10 0.30 ±0.05 
Treated n=3 0.48 ±0.08 
0.41 ±0.03 
 
 
                       Table 1: Up-take kinetic parameters 
 
 
 
4.3.5 [
3
H]Paroxetine binding assay 
 
The Scatchard analysis on untreated and β- TPA-treated cell membranes did not showed 
serotonin transporter expression. 
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4.4 Discussion 
 
The evidence that SERT is present in megakaryoblasts suggests the physiological relevance 
of a balanced control of 5-HT levels during the differentiation processes leading to platelet 
formation (Liu YS et al 2006; Yang M et al 2007). After 8 days of MEG-01 cell culture 
with β-TPA, significant cell morphological variations were observed, accompanied by 
changes in SERT immunostaining, from a perinuclear (undifferentiated cells) to a 
cytoplasm-diffuse (differentiated cells) fluorescence pattern. In β-TPA activated MEG-01 
cells a maximal increase of SERT mRNA was observed after 3 day of stimulation, reaching 
the steady state plateau; a moderate increase in protein expression was noticeable after 8 
days of culture in β-TPA, as shown by densitometric analysis of SERT immunoblot band 
and, even if not significantly, by 5-HT uptake results. 5-HT re-uptake experiments have 
shown that SERT is present in the plasma membrane of MEG-01 cells. Western blot 
revealed a single SERT band in control and treated cells, with an apparent size of 71 KDa, 
a M.W. comparable to that commonly reported for SERT in human brain and platelets (67-
75 KDa). These findings demonstrate that megakaryoblastic cells increase SERT 
expression during megakaryocytopoiesis and that differentiation into megakaryocyte and 
proplatelet-like formation ensures an adequate SERT reserve and 5-HT storage in 
circulating platelets. The enhancement of SERT expression in β-TPA treated cells seems in 
apparent contradiction with β-TPA early events observed in platelets (Marazziti D et al 
1999c; Jayanthi LD et al.2005; Carneiro AM et al. 2006). Nevertheless, some authors have 
reported that 1 µM β-TPA is able either to reduce (after 2h) or to stimulate (after 16 h) 
SERT uptake velocity in JAR placental cells (Ramamoorthy JD et al 1995). Jiang and 
coauthors (2002) have observed that both fibronectin and protein kinase C-dependent 
ERK1/2 MAPK activities are essential to promote megakaryoblastic differentiation. These 
authors have demonstrated that activation of protein kinase C alone (serum free β-TPA 
stimulation) is not able to promote a full megakaryocytopoiesis process. Thus, the observed 
SERT increase might depend from β-TPA-protein kinase C pathways and other signaling 
cascades. The protein kinase network and downstream signal convergent MAPK pathways 
could play a key role in SERT modulation. Proteomic analysis and gene expression studies 
together the use of selective protein kinase (also protein kinase C) or MAPK inhibitors will 
clarify the signaling pathways involved. On the basis of results we hypothesize that our 
findings derived from an equilibrium between different SERT regulatory effects: 
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differentiation events, inducing morphological changes and leading to the formation of 
cytoskeleton-organized cells with 5-HT storage vesicles (Ogura M et al 1998), increase 
total SERT protein density (necessity to accumulate 5-HT in dense granules); 
phosphorylation, down-regulation and trafficking mechanisms (linked to cytoskeleton 
formation) can start having influence on SERT protein expression and function, especially 
in late events of megakaryocytopoiesis. This could explain the observed discrepancy 
between SERT mRNA and protein expression after 8 days of treatment with β-TPA. We 
cannot, in fact, exclude that our Western blot protein extracts were enriched fractions of 
cytoplasm and plasma membrane components. These data seem to be in accordance with 
binding results obtained on cell membranes. Confocal microscopy of MEG-01 cells 
activated by β−TPA will verify SERT localization during early and late differentiation 
events. Since diverse protein regulatory patterns are present in immature megakaryoblasts 
cells as regards to pro-platelets and platelets (Tytgat GAM et al. 2002), the MEG-01 model 
should be primarily applied as a developmental model, for investigations regarding 
molecular differentiation events. For instance, it should be mentioned that a SERT 
regulatory endoproteolytic cleavage has been observed in human platelets, producing 
fragments of different size after immunoblot analysis, whereas a single SERT band was 
resolved in MEG-01 cell extracts, using the same primary antibodies, as here reported.  
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5. Future studies 
 
Megakaryoblastic MEG-01 differentiation is a complex phenomenon leading to up or 
down-regulation of a variety of genes (Isakari Y et al 2009).  Nevertheless, taking into 
account all limits, the use of MEG-01 cells can be the starting point for many investigations 
as the evaluation of hormone and transmitter effects on megakaryoblastic differentiation. 
Moreover, this cell line could be a cellular model to screen those of obesity serum factors 
are mostly important for long-term SERT down or up-regulation.  
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